Yuhua Wang

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

Kim Papp, Richard G. Langley, Mark Lebwohl et al. · The Lancet · 2008 · 1.3K citations

Immunology, Clinical Trials, Clinical Dermatology +7

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial

Iain B. McInnes, Arthur Kavanaugh, Alice B. Gottlieb et al. · The Lancet · 2013 · 789 citations

Rheumatoid Disorder, Rheumatology, Autoimmune Disease +11

A Human Interleukin-12/23 Monoclonal Antibody for the Treatment of Psoriasis

Gerald G. Krueger, Richard G. Langley, Craig L. Leonardi et al. · New England Journal of Medicine · 2007 · 780 citations · Full text

Three Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis

Atul Deodhar, Lianne S. Gensler, Joachim Sieper et al. · Arthritis & Rheumatology · 2018 · 311 citations · Full text

Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis

Howard Sofen, Stacy Smith, Robert Matheson et al. · Journal of Allergy and Clinical Immunology · 2014 · 298 citations · Full text